[BREAKING] Overlooked Mineral REVERSES Alzheimer’s

If you’ve been told there’s nothing you can do to prevent… or even reverse… Alzheimer’s disease, that story just changed.

Mainstream medicine is finally waking up to a cheap, overlooked mineral with the ability to reverse memory loss and stop Alzheimer’s at the source.

Their study was published late last year…  and was just covered by a major medical news site a few days ago.

But we reported on these benefits 5 years ago.

Once again, the medical establishment is playing catch-up

So here’s what the mainstream has been slow to understand – and how you can put this memory-preserving mineral to work for you.

For years, lithium has been associated with psychiatric drugs given at very high doses—the kind that require prescriptions and close monitoring.

But that’s not what this study looked at.

In a landmark paper published in Nature, researchers tested what happens when the brain is exposed to very low, nutritional doses of lithium—levels closer to what you’d find in supplements or mineral-rich water.

The results were striking.

In Alzheimer’s-model mice, low-dose lithium orotate reduced toxic brain plaques by up to 70% and almost completely reversed memory loss, dramatically improving cognitive performance.

In the same Nature paper, researchers examined human Alzheimer’s brain tissue and found that lithium restored key cellular cleanup systems that are typically shut down in the disease—mechanisms responsible for clearing toxic proteins like amyloid and tau.

In other words, lithium didn’t just improve symptoms.

It reactivated pathways the Alzheimer’s brain had lost.

That’s why researchers concluded lithium acts as a disease-modifying agent, not just another temporary fix.

And it explains why medical news outlets are suddenly paying attention.

The protective effects of low-dose lithium have been quietly documented for years—linked to better cognitive outcomes, lower dementia rates, and greater brain resilience in aging populations.

(Which is how we reported on it 5 years ago.)

This raises an obvious question…

If something this simple can help protect memory and brain function…

Why did it take mainstream medicine so long to catch up?

Because lithium carries baggage.

For decades, doctors only viewed it through one lens: high-dose psychiatric medication—the kind that requires blood monitoring and comes with real risks.

That outdated framing caused them to overlook something critical.

Dose matters more than the mineral itself.

At ultra-low levels, lithium behaves less like a drug and more like a neuroprotective nutrient—one the human brain has quietly relied on for thousands of years through trace exposure in food and water.

In fact, population studies have found that regions with naturally higher lithium levels in drinking water have lower rates of dementia and cognitive decline.

But there’s no profit in trace minerals. No blockbuster drug.

So research stalled…until neurodegeneration reached crisis levels.

Now that Alzheimer’s rates are exploding—and drug failures are piling up—scientists are being forced to revisit what was ignored.

And now a certain form has been approved as a prescription drug. No surprise there.

But you can find lithium aspartate or lithium orotate from several quality makers at your local health food store or online.

Life Extension offers a supplement with just 1mg (or 1000mcg). And remember low doses are key. https://www.lifeextension.com

One reviewer said he felt better the very first time he took it.

The question isn’t whether lithium works anymore.

It’s whether you wait for the system to catch up…

Or act on what the science is already showing.

Ray Thatcher
Research Director, Health Sciences Institute

Sources:

• Aron, L., Ngian, Z.K., Qiu, C. et al. Lithium deficiency and the onset of Alzheimer’s disease. Nature 645, 712–721 (2025). https://doi.org/10.1038/s41586-025-09335-x
• Kessing LV, Gerds TA, Knudsen NN, et al. Association of Lithium in Drinking Water With the Incidence of Dementia. JAMA Psychiatry. 2017;74(10):1005–1010. doi:10.1001/jamapsychiatry.2017.2362